The Rise of Non Invasive Glucose Monitoring: Biolinq Shine Explained
- Oct 21, 2025
- 5 min read
Updated: May 7
I've been wearing a CGM for years. And I'm going to be completely honest with you:I still flinch when I insert a sensor.
Twenty-five-plus years of T1D. I know exactly how it works. I know it's a tiny filament. I know insertion is over in a second. Doesn't matter. There's still a moment where my body goes
nope.
So when the FDA granted de novo classification to Biolinq Shine — a glucose sensorwith no needle — I perked up. Not because it's designed for people like me (it's not,and I'll explain why). But because I see clients all the time who want glucose data and just cannot bring themselves to insert a traditional sensor.
If that's you, or someone you love? Keep reading.
What “De Novo Classification” Means
The FDA granted Biolinq Shine de novo classification as a new category of glucosesensor for adults with type 2 diabetes who don't use insulin (FDA.gov,2025). Translation: they created a brand-new regulatory bucket just for this device.
Most devices get cleared through the 510(k) process, which compares a new product to something already on the market. De novo classification is different. It's reserved for technologies that don't fit any existing category. When the FDA has to invent a category, that tells you something. The technology is doing something genuinely new.
How the Biolinq Shine Works
Biolinq Shine uses a microsensor array that sits much closer to the skin surface than a traditional CGM, reportedly up to 20 times shallower than conventional sensors (Biolinq, 2025). No filament. No insertion. It looks, and I mean this affectionately, like a tiny acupuncture mat stuck to your arm.
It still measures glucose from interstitial fluid. Just at a much more superficial depth. The results show up as color-coded LEDs right on the patch:
🟦 Blue: In range
🟨 Yellow: Above range
Spiffy.
The companion mobile app translates these color signals into trend data, showing how glucose shifts relate to your activity and sleep patterns.
What Makes It Different
The biggest breakthrough is comfort. For people living with type 2 diabetes who aren’t on insulin, traditional CGMs can feel intimidating (honestly, needles are intimidating for everyone...)
Biolinq Shine changes that. It provides continuous glucose awareness without requiring needle insertion or calibration.
Right now, it gives qualitative feedback indicating if glucose is “in range” or “above range” rather than exact numerical values. It’s not meant for insulin dosing, but it offers a more approachable option for people who want feedback and cannot access one of the main stream CGM's like Dexcom and Libre.
I'm pretty pumped about this type of data. It helps the user focus more on trends and the big picture view. Too often, my clients get bogged down in perfectionism when using traditional CGM's. I would totally recommend this to clients that don't need the exact numerical data.
What We Don't Know Yet
Here's where I pump the brakes a little. Biolinq Shine measures glucose at a shallower depth than traditional CGMs. As of this writing, no peer-reviewed accuracy data has been published, though studies are underway (Biolinq, 2025). The company hasn't released clinical trialresults publicly yet.
FDA de novo clearance means the device is safe and does what it claims. It doesn't tell us how closely readings track against fingerstick values or established CGMbrands. According to Biolinq's own materials, Shine is intended to show trends and patterns, not replace calibrated glucose monitoring for clinical decisions.
That framing is honest, and I respect it. I'm not saying it doesn't work. I'm saying we don't have the data yet to know how well it works. And for a device in this category, that distinction is worth sitting with.
What's Coming Next — and Why SGLT2 Users Should Pay Attention
Biolinq has described plans for a multi-analyte biosensor platform. Future versions could measure lactate, ketones, and other metabolic markers alongside glucose (Biolinq, 2025).
That's a significant development for anyone on SGLT2 inhibitors like Jardiance or Farxiga. These medications carry a small but real risk of euglycemic DKA — DKA with seemingly normal blood sugars, which makes it harder to catch and harder to recognize. Continuous ketone monitoring alongside glucose could give people a meaningful early warning signal. That's not a nice-to-have. For this population, it's genuinely useful.
Biolinq has announced a U.S. launch planned for early 2026. Pricing and insurance coverage are still unknown. There's also speculation it could eventually be available over the counter, which would be a real access win for people who can't get traditional CGMs covered.
Beyond Glucose: What’s Coming Next
Biolinq’s long-term goal is a multi-analyte biosensor platform—meaning future versions might measure lactate, ketones, or other metabolic markers alongside glucose.
That could be especially valuable for people using SGLT2 inhibitors like Jardiance or Farxiga, which carry a small risk for euglycemic diabetic ketoacidosis (DKA). Detecting ketones continuously could provide a critical early warning.
Biolinq plans a U.S. launch in early 2026, though pricing and insurance coverage remain unknown. Because it provides qualitative data, there’s speculation it could eventually be available over the counter, potentially making it more affordable than standard CGMs.
Frequently Asked Questions
Is Biolinq Shine available now?
Not yet. Biolinq announced plans for a U.S. launch in early 2026, but exact availability and pricing haven't been confirmed as of this writing. Check biolinq.com for updates as the launch date approaches.
Can people with T1D use Biolinq Shine?
Currently, no. The FDA de novo classification covers adults with type 2 diabetes who don't use insulin. It's not cleared for insulin dosing decisions and isn't designed to replace the precise glucose data T1D management requires.
Will insurance cover Biolinq Shine?
Unknown. Because it provides qualitative rather than numerical data, there's speculation it could eventually be sold over the counter, which might make it more accessible than traditional CGMs. No insurance coverage details have been announced.
How accurate is Biolinq Shine compared to Dexcom or Libre?
Peer-reviewed accuracy data hasn't been published yet as of May 2026. Clinical studies are underway. The device measures glucose at a shallower depth than conventional CGMs, which may affect signal quality. Wait for study results before drawing firm conclusions.
TL;DRThe FDA gave Biolinq Shine de novo classification — a brand-new device category fora genuinely novel needle-free glucose sensor. It's designed for adults with T2D whodon't use insulin and gives directional feedback (in range / above range) viacolor-coded LEDs, not numbers. No peer-reviewed accuracy data yet. A multi-analyteversion measuring ketones and lactate is in the pipeline, which matters especiallyfor people on SGLT2 inhibitors. U.S. launch planned for early 2026.
Sources
U.S. Food and Drug Administration. "De Novo Classification Request for Biolinq Shine Glucose Biosensor." Retrieved 2026-05-05. https://www.fda.gov/medical-devices/
(Search: "Biolinq de novo" for exact decision summary page.)
Biolinq, Inc. "Biolinq Shine: How It Works." Retrieved 2026-05-05.
(Source for 20x shallower depth claim and multi-analyte platform roadmap.)
Biolinq, Inc. "Biolinq Shine Intended Use Statement." Retrieved 2026-05-05. https://www.biolinq.com
(Qualitative-only feedback; not intended for clinical dosing decisions.)